Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Extraskeletal Ewing sarcoma is covered by other ESMO Guidelines: in general, the same principles for these tumours in children apply to adults. This is also the case for embryonal and alveolar rhabdomyosarcoma, which are exceedingly rare in adults. On the other hand, pleomorphic rhabdomyosarcoma is viewed as a high-grade adult-type soft tissue sarcoma. Gastrointestinal stromal tumours are covered by the dedicated ESMO Clinical Practice Guidelines. Kaposi’s sarcoma is excluded.

[1]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[2]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Cesne,et al.  High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Casper,et al.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Wanebo,et al.  Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.

[6]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Weiss,et al.  Therapy of desmoid tumors and fibromatosis using vinorelbine. , 1999, American journal of clinical oncology.

[8]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Casali,et al.  Low‐dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis , 2001, Cancer.

[11]  A. Davis,et al.  Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial , 2002, The Lancet.

[12]  Samuel Singer,et al.  Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.

[13]  C. Raut,et al.  Retroperitoneal sarcomas: Combined‐modality treatment approaches , 2002, Journal of surgical oncology.

[14]  R. Benjamin,et al.  Desmoid tumors respond to chemotherapy: defying the dogma in oncology. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[16]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Blay,et al.  Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Farrokhyar,et al.  A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.

[20]  J. Blay,et al.  Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[22]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Blay,et al.  Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Casali,et al.  Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.

[26]  Robin L. Jones,et al.  Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.

[27]  J. Roth,et al.  Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. , 2009, The Annals of thoracic surgery.

[28]  J. Thigpen.  Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study , 2009 .

[29]  L. Mariani,et al.  Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.

[30]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[31]  L. Mariani,et al.  Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control , 2010, Annals of Surgical Oncology.

[32]  C. Antonescu,et al.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Antonescu,et al.  Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) , 2010, Cancer.

[34]  M. van Glabbeke,et al.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Peter Wust,et al.  Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.

[36]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Ip,et al.  Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[38]  P. Casali,et al.  Dermatofibrosarcoma protuberans‐derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib , 2011, International journal of cancer.

[39]  C. Antonescu,et al.  Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis , 2010, Clinical Cancer Research.

[40]  A. Eggermont,et al.  Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  B. Quade,et al.  Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms , 2012, PloS one.

[42]  J. Verweij,et al.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[43]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[44]  A. D. Dei Tos,et al.  Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. D. Dei Tos,et al.  Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  M. van de Rijn,et al.  The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas: A Histologically High-grade and Clinically Aggressive Tumor , 2012, The American journal of surgical pathology.

[47]  L. Mariani,et al.  Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Blay,et al.  Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  A. D. Dei Tos,et al.  Sunitinib malate in solitary fibrous tumor (SFT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Li-Xuan Qin,et al.  A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas After Limb-Sparing Surgery Without Adjuvant Radiation , 2012, Annals of surgery.

[51]  J. Rauh-Hain,et al.  Endometrial Stromal Sarcoma: A Systematic Review , 2013, Obstetrics and gynecology.

[52]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[53]  Robin L. Jones,et al.  Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.

[54]  J. Wathen,et al.  Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma , 2013, Cancer.

[55]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[56]  S. Steinberg,et al.  Cediranib for metastatic alveolar soft part sarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  C. Stiller,et al.  Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.

[58]  C. Nezhat,et al.  Evaluating the risks of electric uterine morcellation. , 2014, JAMA.

[59]  C. Mussi,et al.  Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm-a position paper from the Italian and the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  P. Dileo,et al.  What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.

[61]  T. Group,et al.  Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group , 2014, Annals of Surgical Oncology.

[62]  K. Rankin,et al.  Preoperative Versus Postoperative Radiotherapy in Soft-Tissue Sarcoma of the Limbs: A Randomised Trial , 2014 .

[63]  P. Schwartz,et al.  Hormonal Therapy for Aggressive Angiomyxoma: A Case Report and Proposed Management Algorithm , 2014, Journal of lower genital tract disease.

[64]  U. Mansmann,et al.  Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter Study , 2014, Annals of surgery.

[65]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[66]  S. Steinberg,et al.  Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial , 2014, Annals of Surgical Oncology.